Gland Pharma
BSE 543245
7 stories, newest first.
- USFDA unannounced inspection at Dundigal formulation facility concludes with four Form 483 observations
- Gland Pharma to host Q2 FY27 earnings conference call on November 6, 2026 at 18:30 IST
- Board meeting on November 06, 2026 to consider unaudited results for the quarter and half year ended September 30, 2026
- Board approves USD 21 million investment in US arm; 60% stake in Novelstar Pharma
- Board approves USD 21 million investment in US arm to take 60% of Novelstar Pharma; board changes
- Gland Pharma Ltd promoter sells 6.00% stake, holding falls to 45.76%
- Srikanth Chauhan of Kotak Securities recommended Gland Pharma as it crosses an important technical level
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.